Covaxin found to be safe and immunogenic in 2-18 age group says Bharat Biotech

New Delhi : Vaccine maker Bharat Biotech said on Thursday that the BBV152 (Covaccine) vaccine has proven to be safe and provide good immunity in phase II and phase III studies in children. Bharat Biotech said the Bharat Company had conducted Phase II and III separate studies to evaluate the safety, response and immunity of the vaccine in healthy children and adolescents aged 2-18 years.

Krishna Ella, Chairman and Managing Director, Bharat Biotech said, “The clinical trial data of Covaccine in children is very encouraging. Vaccine safety is important for children and we are pleased to report that Covaccine has now proven to be superior in terms of safety and immunity in children. We have now achieved our goal of developing a safe and effective COVID-19 vaccine for adults and children.

The clinical trials of the vaccine conducted on children between June-September this year have shown strong protection and immunity. Its data was submitted to the Central Drugs Standard Control Organization (CDSCO) during October 2021 and recently the Drugs Controller General of India (DCGI) allowed emergency use of Covaccine for children in the age group of 12-18 years. On behalf of the company, it was said that no serious adverse events were reported in the study of the vaccine.